Hill Raymond George sold (to issuer) 1,365,532 shares of ADXN
Hill Raymond George sold (to issuer) 1,365,532 shares of Addex Therapeutics Ltd. (ADXN) on 2026-09-02.
How this was made
The 30-second read
Why it matters
The filing is the first public disclosure of this insider transaction, providing new information to the market.
Market read
First report of a large insider sell; may influence short‑term price action.
What to watch
Lack of disclosed price and reason for sale limits assessment; could be part of a pre‑planned 10b5‑1 plan.
Background
Form 4 filing discloses a director's complete exit from Addex Therapeutics, a biotech listed on Nasdaq.
Ticker impact
Director Hill Raymond George sold his entire 1,365,532 shares, reducing holdings to zero.
Short-term downward pressure expected as market digests the exit of a director.
The sale represents a large block for a micro‑cap biotech; insider exits often weigh negatively on price.
Market effects
May raise concerns for biotech sector investors about insider confidence.
Limited to US biotech investors; no broader regional effect.
Minimal global impact; primarily relevant to ADXN shareholders.
Counterpoint
Insider sell could be unrelated to company fundamentals; may present a buying opportunity if the stock is oversold.
Key entities
- CompanyAddex Therapeutics Ltd.
Biotech firm listed on Nasdaq under ticker ADXN.
- IndividualHill Raymond George
Director of Addex Therapeutics who sold his shares.